Aldosterone antagonism in heart failure

被引：5

作者：

Richards, AM ^{[1
]}

Nicholls, MG ^{[1
]}

机构：

[1] Christchurch Sch Med, Cardioendocrine Res Grp, Christchurch, New Zealand

来源：

LANCET | 1999年 / 354卷 / 9181期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：789 / 790

页数：2

共 11 条

[1] EFFECTS OF ADDING SPIRONOLACTONE TO AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR IN CHRONIC CONGESTIVE-HEART-FAILURE SECONDARY TO CORONARY-ARTERY DISEASE [J].

BARR, CS ;

LANG, CC ;

HANSON, J ;

ARNOTT, M ;

KENNEDY, N ;

STRUTHERS, AD .

AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (17) :1259-1265

[2] ANTI-ALDOSTERONE TREATMENT AND THE PREVENTION OF MYOCARDIAL FIBROSIS IN PRIMARY AND SECONDARY HYPERALDOSTERONISM [J].

BRILLA, CG ;

MATSUBARA, LS ;

WEBER, KT .

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1993, 25 (05) :563-575

[3]

Hjalmarson Å, 1999, LANCET, V353, P2001

[4]

Lechat P, 1999, LANCET, V353, P9

[5]

NICKLAS JM, 1992, NEW ENGL J MED, V327, P685

[6] The effect of carvedilol on morbidity and mortality in patients with chronic heart failure [J].

Packer, M ;

Bristow, MR ;

Cohn, JN ;

Colucci, WS ;

Fowler, MB ;

Gilbert, EM ;

Shusterman, NH .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (21) :1349-1355

[7]

Pitt B, 1996, AM J CARDIOL, V78, P902

[8] The effect of spironolactone on morbidity and mortality in patients with severe heart failure [J].

Pitt, B ;

Zannad, F ;

Remme, WJ ;

Cody, R ;

Castaigne, A ;

Perez, A ;

Palensky, J ;

Wittes, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) :709-717

[9]

Struthers A D, 1996, J Card Fail, V2, P47, DOI 10.1016/S1071-9164(96)80009-1

[10]

SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429

← 1 2 →